Histocell concludes capital increase for international launch of Reoxcare Histocell, a specialist in regenerative medicine and cell therapy, has concluded the first funding round in line with its 2015-2020 Strategic Plan. Its total investment requirements are €4M, which will mostly be earmarked to developing three health products and concluding phases I/IIa of clinical trials for […]